JASPER THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable and Other Operating Assets
JASPER THERAPEUTICS, INC. (JSPR) reported Increase (Decrease) in Accounts Receivable and Other Operating Assets of -$663.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets · last filed 2023-11-09
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2023-09-30 was $0.00.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2023-06-30 was $0.00.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2023-03-31 was -$663.00K.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2021-12-31 was $0.00.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for fiscal 2022 was $663.00K.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for fiscal 2021 was -$600.00K.
| Period end | Increase (Decrease) in Accounts Receivable and Other Operating Assets 3 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 6 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 9 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | -$663.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$663.00K 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | -$663.00K 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $663.00K 10-K · filed 2023-03-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$600.00K 10-K · filed 2023-03-08 | ||
| 2021-09-30 | -$600.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |